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Human T cell leukemia/lymphoma virus type I DNA 
and polymyositis/dermatomyositis: comment on the 
article by Sherman et al
To the Editor:
In their recent article, Sherman et al showed an 
association between human T cell leukemia/lymphoma virus 
type I (HTLV-I) and polymyositis in patients from Jamaica, 
an endemic area for HTLV-I infection (1). The case of their 
patient MR was of great interest because he had negative 
serologic results for HTLV-I.
We have previously reported the case of a female 
polymyositis/dermatomyositis patient from France who was 
HTLV-I seronegative but in whom HTLV-I DNA sequences 
were detected in peripheral blood lymphocytes, by gene 
amplification utilizing the polymerase chain reaction (PCR) 
assay (2). The search for a possible HTLV-I infection in this 
patient was prompted by the presence of certain unusual 
features which have been previously noted in HTLV-I- 
seropositive patients. She had an intense CD8+ lymphocytic 
alveolitis, a pulmonary manifestation observed in patients 
with HTLV-I-associated myelopathy (3). She also reported 
xerostomia and xerophthalmia. Findings of a Schirmer’s test 
were positive, and rose bengal staining of the conjunctiva 
was abnormal. Biopsy of the minor salivary glands demon­
strated an interstitial lymphoplasmacytic infiltration with 
dilatation of the ducts. The duct of the epithelium was 
atrophic, and moderate interstitial fibrosis was observed. A 
link between HTLV-I infection and sicca syndrome has been 
suggested (4). Finally, she later developed a pyramidal 
syndrome in which deep tendon reflexes were brisk and 
associated with bilateral Bakinski signs, as has been noted in 
HTLV-I-seropositive patients with polymyositis (5). In ac­
cordance with the proposal by Sherman et al that HTLV-I 
may play a role in polymyositis in patients from HTLV-I- 
endemic areas, we would suggest performing PCR analysis 
for HTLV-I infection in patients from non-endemic areas 
who have an unusual form of dermatomyositis associated 
with pyramidal signs, sicca syndrome, and pulmonary lym­
phocytic involvement.
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American College of Rheumatology preliminary 
definition of improvement in rheumatoid arthritis: 
comment on the article by Felson et al
To the Editor:
We read with great interest the article by Felson et al 
regarding the American College of Rheumatology (ACR) 
preliminary definition of improvement in rheumatoid arthri­
tis (RA) (1). We share the authors’ opinion that the topic of 
assessing and analyzing individual treatment response in RA 
clinical trials is very important. We fully agree that the use of 
a single measure for improvement increases the power of a 
trial, and that we should aim for standardization of a 
definition for improvement since this makes it possible to 
compare different trials.
In their study, Felson et al selected a definition of 
improvement based on 1) correspondence with rheumatolo­
gists’ impressions about the improvement of “paper” pa­
tients (n = 43), 2) the most powerful discrimination between 
active treatment and placebo (or less active) treatment, and 
3) ease of use/credibility. Although we appreciate the 
method used to select this definition, we would like to make 
some minor comments.
First, to what extent do rheumatologists’ impres­
sions of paper patients for whom only 7 variables at 2 time 
periods are described reflect the impressions of rheumatol­
ogists in daily clinical practice? Does the selection of paper 
patients “ near expected thresholds for improvement (20— 
45% improvement in at least 3 outcomes)” not implicate bias 
by using a predetermined definition of improvement? Sec­
ond, is the difference between placebo and active treatment 
identified with the improvement definition a clinically rele­
vant difference? Is there an association with outcome mea­
sures in RA, such as radiographic progression and functional 
capacity? Is the measure sensitive to detect smaller differ­
ences between two active treatments?
Recently, we developed response criteria based on 
the Disease Activity Score, using a different approach (2). 
During the European League Against Rheumatism 
(EULAR) meeting in Amsterdam (June 1995), these re-
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sponse criteria were accepted as the EULAR response 
criteria by the Standing Committee on International Clinical 
Studies including Therapeutic Trials. The 3 major differ­
ences between the ACR criteria and the EULAR criteria are 
as follows: 1) The EULAR response criteria are based on the 
capacity to discriminate between high and low disease 
activity in patients seen in daily clinical practice, while the 
ACR criteria are based on the discrimination between active 
drug-treated and placebo-treated patients in clinical trials 
(an approach that has its pros and cons) (3). 2) The EULAR 
response criteria combine change in disease activity with the 
level of disease activity reached, while the ACR criteria are 
based on change from baseline alone. 3) The EULAR 
response criteria have 3 categories (good, moderate, nonre­
sponse), while the ACR criteria have 2 categories.
Despite these differences, both measures have been 
developed to determine treatment response in individuals. In 
the absence of a gold standard, both the ACR and the 
EULAR definitions of response should be used and com­
pared in as many trials as possible. As a first step, we 
recently presented a comparison between these 2 response 
definitions in 1 double-blind clinical trial (4). Currently we 
are comparing the 2 approaches to defining response in 
several double-blind trials (5). The most useful definition will 
be the one that can best predict clinically relevant outcomes 
in RA patients, combined with the ability to differentiate 
between more and less effective treatments.
Anke van Gestel, MSc 
Piet van Riel, MD, PhD 
University Hospital Nijmegen 
Nijmegen, The Netherlands
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Reply
To the Editor:
The other committee members and I appreciate the 
interest of Drs. van Gestel and van Riel in our article 
reporting the ACR preliminary definition of improvement in
RA. First, let me respond to their specific questions about 
the development of the definition of improvement.
In surveying rheumatologists to get their impressions 
of which patients improved, we chose data on the 7 ACR/ 
EULAR core set measures presented at 2 points in time 
because we wanted to duplicate the trial situation in which 7 
core set measures are recommended (1) and in which 2 
points in time (the beginning and end of trial) may be used to 
define whether a patient has improved. Giving physicians 
information on multiple time points may lead them to decide 
on improvement based on the time course of changes, rather 
than actual changes per se.
Van Gestel and van Riel are not correct in assuming 
that we selected only patients near thresholds of improve­
ment. We chose patients randomly from all strata in clinical 
trials, and therefore selected percentage improvements that 
were markedly different from 20-45%. Because surveys 
from the Outcome Measures in RA Clinical Trials confer­
ence (2) showed that improvements of ~20-45% in core set 
parameters corresponded best with clinicians’ impressions 
of patients having improved, we selected this range of 
improvement as one from which we oversampled patients in 
trials. Therefore, while our patients represented all experi­
ences in trials including worsening and much greater im­
provement, we had more patients in the 20-45% improve­
ment range than in others.
The ACR improvement definition incorporates all of 
the core set measures, and the core set measures were 
selected because they correlate with gold standard measures 
such as radiographic progression and functional capacity (1). 
Furthermore, the core set actually includes measures of 
functional capacity. Therefore, we are confident that the 
ACR definition of improvement correlates with both radio- 
graphic deterioration and functional status. Conversely, 
failure to improve is likely to portend worse functional status 
and radiographic deterioration. Nonetheless, both of these 
need to be confirmed in prospective studies.
In contrast to the assertion by van Gestel and van 
Riel, the ACR criteria were tested against comparative trials 
and effectively differentiated between effective second-line 
drugs in RA (see Figure 2 of ref. 3). They also have been 
shown in a recent published trial (4) to discriminate well 
between patients treated with combination therapy and 
those receiving single second-line drug therapy, suggesting 
that, with the use of the ACR improvement criteria, one can 
detect small but important clinical differences between ef­
fective regimens.
Van Gestel and van Riel list 3 important differences 
between the EULAR and the ACR definitions of improve­
ment on which I would like to expand, and I will also list 
additional differences. First, the ACR improvement defini­
tion was constructed to correspond to clinicians’ impres­
sions of improvement, whereas the EULAR response crite­
ria were constructed based on decisions about starting and 
stopping second-line drugs, decisions that are not always 
related to improvement.
Second, the ACR criteria use all 7 measures incor­
porated into the ACR/EULAR/WHO core set of measures 
for disease activity, a group of measures agreed upon by the 
EULAR group. Nonetheless, the EULAR response criteria 
use the Disease Activity Score (DAS) index, which focuses
